ADCendo

About:

ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs.

Top Investors: Novo Holdings, RA Capital Management, HealthCap, Gilde Healthcare, Novo Nordisk Foundation

Description:

ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.

Total Funding Amount:

$115M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Copenhagen, Hovedstaden, Denmark

Founded Date:

2017-01-01

Contact Email:

info(AT)adcendo.dk

Founders:

Christoffer Nielsen, Henrik Stage, Lars H. Engelholm, Niels Behrendt

Number of Employees:

11-50

Last Funding Date:

2024-05-29

IPO Status:

Private

Industries: